Nifty
Sensex
:
:
24583.80
78542.44
13.15 (0.05%)
43.27 (0.06%)

Pharmaceuticals & Drugs - Domestic

Rating :
70/99

BSE: 506820 | NSE: ASTRAZEN

8090.00
10-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  8259
  •  8259
  •  7722
  •  8191.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  47975
  •  386034848
  •  9849.5
  •  7551.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,193.25
  • 119.05
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,744.63
  • 0.45%
  • 23.31

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.08%
  • 13.76%
  • FII
  • DII
  • Others
  • 2.68%
  • 6.01%
  • 1.47%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.39
  • 23.08
  • 20.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 21.64
  • 24.91
  • 7.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.05
  • 24.94
  • 5.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 107.93
  • 107.65
  • 111.76

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.21
  • 20.77
  • 24.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 63.79
  • 63.95
  • 68.18

Earnings Forecasts:

(Updated: 08-08-2026)
Description
2026
2027
2028
2029
Adj EPS
60
-9
-
-
P/E Ratio
134.83
-898.89
-
-
Revenue
-
-
-
-
EBITDA
1390
1680
-
-
Net Income
380
480
-
-
ROA
230
300
-
-
P/B Ratio
-
-
-
-
ROE
-
-
-
-
FCFF
16
17
-
-
FCFF Yield
-
-
-
-
Net Debt
-
-
-
-
BVPS
-
-
-
-

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • Astrazeneca Pharma - Quarterly Results
    11th Aug 2026, 00:00 AM

    Read More
  • AstraZeneca Pharma gets CDSCO nod to market Enhertu for additional indication
    10th Aug 2026, 12:28 PM

    The receipt of this permission paves way for the marketing of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.